Tuesday, 22 November 2022

BioLargo’s Partner Ikigai Begins Sales of Pooph at Walmart

Pooph: The Pet Odor Remover that Takes Stink Out of the Equation  

Westminster, CA – November 22, 2022 – BioLargo, Inc. (OTCQB:BLGO), a developer of sustainable cleantech technologies and full-service environmental engineering company, is pleased to announce that the Pooph™ pet odor control product line is now available at select Walmart stores.

Pooph, which is based on BioLargo’s proprietary odor control technology, is marketed by Ikigai Marketing Works, LLC through a national advertising campaign (see www.Pooph.com). Walmart is the first retailer for a planned national retail distribution, and begins with Pooph in over 600 stores across the United States.

Jane Pak, CEO of Ikigai commented, “Sales of Pooph have exceeded our expectations and forecasting. Availability of Pooph at 681 Walmart stores is just the beginning of what we expect to be national retail distribution. The team at BioLargo have been great at supporting our success. Our team is excited to continue watching Pooph become solidified as a nationally known and trusted consumer packaged goods brand.” 

Dennis P. Calvert, President and CEO of BioLargo said, “The team at Ikigai has continued to grow sales and brand awareness with its highly effective marketing that showcases the product’s complete and rapid odor elimination, and its safety.  We are thankful for the very talented team at Ikigai and look forward to working closely with them to support their continued expansion.”

 

About BioLargo, Inc.

BioLargo, Inc. (OTCQB:BLGO) invents, develops, and commercializes innovative technologies in the cleantech space, including for PFAS contamination, advanced water and wastewater treatment, industrial odor and VOC control, air quality control, and infection control. With over 13 years of extensive R&D, BioLargo holds a wide array of issued patents, maintains a robust pipeline of products, and provides full-service environmental engineering. Our approach is to invent or acquire novel technologies and develop them to maturity through our operating subsidiaries. We have developed a number of key channel partnerships to support the reach of our products and services and maximize their commercial potential. With a keen emphasis on collaborations with academic, municipal, and commercial organizations and associations, BioLargo has proven itself with over 90 awarded grants and numerous pilot projects. We monetize through direct sales, recurring service contracts, licensing agreements, strategic joint venture formation and/or the sale of the IP. See our website at www.BioLargo.com.

Contact Information

Dennis P. Calvert

President and CEO, BioLargo, Inc.

888-400-2863

Safe Harbor Act

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo’s (the “Company”) expectations regarding the impact of the COVID-19 pandemic; anticipated revenue; and plans for future operations. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of the COVID-19 pandemic on the Company’s business, results of operations, financial condition, and stock price; the effect of regional economic conditions on the Company’s business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company’s products. More information on these risks and other potential factors that could affect the Company’s business and financial results is included in the Company’s filings with the SEC, including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.

Monday, 21 November 2022

BioLargo: This Company is Helping Keep The Earth Clean (Benzinga Interview)

Dennis Calvert, President & CEO of BioLargo, Inc. (BLGO) was a guest on Benzinga’s All Access on Nov 18, 2022.

BioLargo invents, develops, and commercializes innovative platform technologies to solve challenging environmental problems like PFAS contamination, advanced water and wastewater treatment, industrial odor and VOC control, air quality control, and infection control. 

Watch the full interview here:

Sequire Spotlight Presents Biolargo (BLGO): An Innovator & Solution Provider For a Clean Environment

Host Jonathan Miller interviews CEO: Dennis Calvert. He states that the culture of service is what brings a good service to the table when it comes to saving our natural resources.

Tuesday, 15 November 2022

BioLargo Achieves 111% Growth to a Record $1.5 Million Revenue for Third Quarter 2022


Conference call scheduled for Wednesday, November 16 at 5:00 pm Eastern

Westminster, CA – November 15, 2022 – BioLargo, Inc. (OTCQB:BLGO), a developer of sustainable cleantech technologies and full-service environmental engineering company, filed its Quarterly Report on Form 10-Q for the three months and nine months ended September 30, 2022, with the SEC yesterday (www.biolargo.com/sec-filings). Here the company has provided highlights from the quarterly report and a discussion of key business initiatives with the most potential to stimulate growth.

The company will hold an investor webcast on Wednesday, November 16, 2022, at 2:00 pm Pacific / 5:00 pm Eastern, at the following link, open to the public: https://www.webcaster4.com/Webcast/Page/2448/47095

BioLargo’s President and CEO Dennis P. Calvert said, “In this quarter we again broke our quarterly revenue record, and have already far surpassed 2021’s total revenues. Our strategy of growing by leveraging our core technology assets through channel partnerships is paying off, as evidenced by the growing success of our pet odor control product partnership. We also expect the commercial roll-out of our PFAS treatment system to play a big role in the future growth of our company.”

Financial highlights

  • Company-wide consolidated revenue for the three and nine months ended September 30, 2022, was $1,500,000 and $3,786,000, which is a 111% and 117% increase over the same periods in 2021; revenue this quarter was a 13% increase compared with the second quarter of 2022.
  • Revenues from ONM Environmental, the company’s odor and VOC control subsidiary, for the three and nine months ended September 30, 2022, were $1,199,000 and $2,499,000, an increase of $779,000 and $1,441,000, from the same periods in 2021. In the third quarter of 2022, this subsidiary generated operating income of $400,000, compared to an operating loss of $72,000 in the same period of 2021.
  • Revenues from third parties for BioLargo Engineering, Science & Technologies, the company’s environmental engineering subsidiary, for the three and nine months ended September 30, 2022, were $283,000 and $1,254,000, an increase of $2,000 and $699,000, from the same periods in 2021.

Commercial highlights

  • Sales of the Pooph branded pet odor control product to Ikigai have risen significantly, accounting for the bulk of the rise in revenue at ONM Environmental. Ikigai intends to continue their national advertising campaign as the product is launched in Walmart and other national retailers.
  • The company secured its first customer to engineer a comprehensive PFAS mitigation plan for a large industrial site. The project’s first phase, the development of a comprehensive PFAS treatment plan, is underway, and subsequent phases are expected to advance in the coming months.
  • The company’s plans to roll out its PFAS treatment technology across the country progressed significantly, with the securing of Product Recovery Management as a contract manufacturer, and a growing number of sales representative organizations that are expected to cover most of North America.
  • BioLargo’s engineering division completed the first phase of some large projects, including the waste-to-energy conversion plant project in South America and the fuel production system project with Ultra Safe Nuclear. Both projects are anticipated to advance to subsequent phases which are of greater scope in the coming months.
  • The company added two new board members to its team: Linda Park and Christina Bray. Both new board members have a background, education, and corporate experience that make them an ideal fit to advance BioLargo’s core organizational goals, and its vision to “make life better” through its cleantech products and services.
  • BioLargo Engineering, Science & Technologies built field units of its PFAS treatment technology the Aqueous Electrostatic Concentrator (AEC) to be used in trial projects whereby customers try out the technology, for a fee, to ensure it accomplishes their water treatment goals and assists them in meeting new water standards for PFAS. Learn more about the company’s PFAS Testing Program (the company’s piloting program) at https://www.biolargoengineering.com/biolargo-pfas-testing-program/.

Correction: an earlier version of this release incorrectly stated, under Financial Highlights, that ONM Environmental generated operating income of $400,000 in the second quarter of 2022. In this corrected version, we state that ONM Environmental generated operating income of $400,000 in the third quarter of 2022 (the quarter being reported on in today's release).


About BioLargo, Inc.

BioLargo, Inc. (OTCQB:BLGO) invents, develops, and commercializes innovative technologies in the cleantech space, including for PFAS contamination, advanced water and wastewater treatment, industrial odor and VOC control, air quality control, and infection control. With over 13 years of extensive R&D, BioLargo holds a wide array of issued patents, maintains a robust pipeline of products, and provides full-service environmental engineering. Our approach is to invent or acquire novel technologies and develop them to maturity through our operating subsidiaries. We have developed a number of key channel partnerships to support the reach of our products and services and maximize their commercial potential. With a keen emphasis on collaborations with academic, municipal, and commercial organizations and associations, BioLargo has proven itself with over 90 awarded grants and numerous pilot projects. We monetize through direct sales, recurring service contracts, licensing agreements, strategic joint venture formation and/or the sale of the IP. See our website at www.biolargo.com.

Contact Information

Dennis P. Calvert

President and CEO, BioLargo, Inc.

888-400-2863

Safe Harbor Act

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo’s (the “Company”) expectations regarding anticipated revenue and plans for future operations, and may be identified by words such as “we believe”. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of the COVID-19 pandemic on the Company’s business, results of operations, financial condition, and stock price; the effect of global and regional economic conditions on the Company’s business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company’s products. More information on these risks and other potential factors that could affect the Company’s business and financial results is included in the Company’s filings with the SEC, including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.

Thursday, 10 November 2022

BioLargo Q3 2022 Earnings Results Webcast and Conference Call on Wednesday, November 16, 2022 - 5 PM Eastern Time

Westminster, CA – November 10, 2022 – BioLargo, Inc. (OTCQB:BLGO), a developer of sustainable technologies and full-service environmental engineering company, announced it will host an investor webcast and conference call on Wednesday, November 16, 2022, at 2:00 pm Pacific / 5:00 pm Eastern. The event, which will be open to the public, will be held to review the company’s financial results for the three and nine months ended September 30, 2022, discuss recent milestones, and conduct a question-and-answer session.

To listen to a live broadcast, go to the site linked below at least 15 minutes prior to the scheduled start time to register and download any necessary audio/video software.

To participate in the live webcast and teleconference:

Webcast Link: https://www.webcaster4.com/Webcast/Page/2448/47095 

Teleconference Domestic:                888-506-0062

Teleconference International:         973-528-0011

Participant Access Code:                796301


To watch or listen to a replay of the webcast or teleconference:

Webcast Replay Expiration:             Friday, November 17, 2023

Teleconference Replay Expiration:     Thursday, November 30, 2022

Teleconference Replay Domestic:     877-481-4010

Teleconference Replay International:     919-882-2331

Replay Passcode:                                      47095


The webcast replay and accompanying presentation materials will be made available on the Investor Relations section of BioLargo’s website at www.biolargo.com/investor-relations


About BioLargo, Inc.

BioLargo, Inc. (OTCQB:BLGO) invents, develops, and commercializes innovative technologies in the cleantech space, including for PFAS contamination, advanced water and wastewater treatment, industrial odor and VOC control, air quality control, and infection control. With over 13 years of extensive R&D, BioLargo holds a wide array of issued patents, maintains a robust pipeline of products, and provides full-service environmental engineering. Our approach is to invent or acquire novel technologies and develop them to maturity through our operating subsidiaries. We have developed a number of key channel partnerships to support the reach of our products and services and maximize their commercial potential. With a keen emphasis on collaborations with academic, municipal, and commercial organizations and associations, BioLargo has proven itself with over 90 awarded grants and numerous pilot projects. We monetize through direct sales, recurring service contracts, licensing agreements, strategic joint venture formation and/or the sale of the IP. See our website at www.BioLargo.com.  

Contact Information

Dennis P. Calvert 

President and CEO, BioLargo, Inc. 

888-400-2863

Safe Harbor Act

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo’s (the “Company”) expectations regarding the impact of the COVID-19 pandemic; anticipated revenue; and plans for future operations. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of the COVID-19 pandemic on the Company’s business, results of operations, financial condition, and stock price; the effect of regional economic conditions on the Company’s business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company’s products. More information on these risks and other potential factors that could affect the Company’s business and financial results is included in the Company’s filings with the SEC, including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.


Tuesday, 8 November 2022

Results from BioLargo’s 18-Month Municipal Wastewater Treatment Pilot in Montreal Presented at National Conference

Westminster, CA – November 8, 2022 – BioLargo, Inc. (OTCQB:BLGO), a developer of sustainable cleantech technologies and full-service environmental engineering company, announced that its subsidiary BioLargo Water presented the results of its municipal wastewater treatment pilot at the Canadian Water and Wastewater Association’s annual conference in Halifax, Nova Scotia. Results presented at the conference cement the company’s patented Advanced Oxidation System (AOS) water treatment technology as a powerful yet energy- and cost-efficient solution for removing emerging contaminants from wastewater.

In the face of an expanding population, aging sewage treatment infrastructure, and the growing concern of hard-to-treat wastewater contaminants like pharmaceuticals (a.k.a., “micropollutants”, identified by the US EPA as “contaminants of emerging concern”), there is a growing global interest in new water treatment technologies that can effectively and affordably remove a broad spectrum of water contaminants while also addressing legacy contaminants like bacteria and viruses.

BioLargo developed its AOS to be the new gold standard technology for tertiary wastewater treatment (i.e., the final step in sewage treatment). The AOS uses proprietary electro-oxidation technology to generate a blend of powerful iodine molecules and hydroxyl radicals inside its patented reaction cell, resulting in rapid and energy-efficient water disinfection and breakdown of organic contaminants.

A commercial-scale AOS unit has been operating, continuously, on-site at a municipal wastewater treatment plant pilot site at a municipality near Montreal, Quebec, for the past 18 months. The purpose of the pilot was to test whether the AOS could remove certain pharmaceutical micropollutants from the municipality’s wastewater more effectively than the plant’s current equipment, as well as to verify that the AOS could operate in a real-world wastewater treatment plant over long periods of time without issue.

Over the course of the pilot, the AOS system significantly improved removal of pharmaceuticals from the plant’s municipal wastewater. Currently, the treatment plant (which does not include any equipment specifically designed for pharmaceutical removal) is able to remove only a portion of each of the targeted contaminants. When the AOS was added to the treatment train, removal efficiency increased to between 84% and 100% (depending on the particular targeted contaminant).

On November 7, 2022, BioLargo Water’s Lead Research Scientist Dr. Laura Patterson-Fortin presented the results of the municipal wastewater treatment pilot at the Canadian Water and Wastewater Association’s flagship annual event, the National Water and Wastewater Conference, in Halifax, Nova Scotia. Dr. Patterson-Fortin presented these results alongside the company’s academic partners from the world-renowned Centre des Technologies de l’Eau (CTE) in Montreal, who oversaw the pilot project’s operation and analyzed its results.

Dr. Richard Smith, President of BioLargo Water, commented, “The AOS is a truly remarkable water treatment technology on the cutting edge of micropollutant treatment. While their regulatory status in the US and Canada is still in the early stages, micropollutants are garnering the attention of regulators in Europe due to their potential to cause environmental damage and affect human health. Many of the leading companies in the water industry have identified micropollutants as a driver for future growth. We intend for the AOS to be ahead of the curve as an effective, energy-efficient option for micropollutant treatment as this market develops globally.”

He continued, “If all the AOS could do was remove pharmaceuticals from wastewater, it would have a bright commercial future as governments around the world adopt new regulations. But the AOS does much more than that – it is also a highly effective, affordable, and energy-efficient water disinfection device that rivals UV – making it deliver exceptional value to wastewater treatment operators seeking to future-proof their operations.”

Thursday, 3 November 2022

BioLargo Adds Linda Park and Christina Bray to Board of Directors

Westminster, CA – November 3, 2022 – BioLargo, Inc. (OTCQB:BLGO), a developer of sustainable cleantech technologies and full-service environmental engineering company, announced it has added two new board members to its team: Linda Park and Christina Bray. Both new board members have a background, education, and corporate experience that make them an ideal fit to advance BioLargo’s core organizational goals, and its vision to “make life better” through its cleantech products and services.

Linda Park is a trusted executive and legal professional with a proven track record of supporting and advising public companies. With corporate board and executive experience at billion-dollar corporations such as her current roles working with Edward Lifesciences in her capacity as Corporate Secretary, Senior Vice President and Associate General Counsel, and Board Member of the Edwards Lifesciences Foundation, and prior work with Western Digital Corporation, Linda brings over 20 years of experience advancing organizations’ corporate governance and strategic goals. She also has many years of experience advising issuer and investment banking clients on corporate and securities matters, mergers and acquisitions, bank financings and capital markets, including initial public offerings. She is also an active partner and thought leader on environmental, social, and corporate governance issues. Linda has an undergraduate degree from Johns Hopkins University, and a law degree from Duke University School of Law.

Christina Bray is a senior finance specialist, entrepreneur, and renewables specialist, and currently serves as the CEO and founder of Bluedot Energies, an innovative company that designs, builds, and manages electric vehicle charging stations for large-scale public and private applications. A rising star in green energy technologies, Christina has significant finance, capital projects, and corporate operation experience, having negotiated M&A activities and managed $1 billion in quarterly loan volume at the solar fintech company Sunlight Financial. She has extensive training including a master’s degree in Military History from Norwich University and an undergraduate degree in Middle Eastern Studies from Yale University. She is well-versed in middle eastern language and society.

“We are so pleased that Linda Park and Christina Bray have joined our Board of Directors,” said Dennis P. Calvert, BioLargo’s CEO. “Both have such significant experience in advancing innovative projects, as well as building and supporting successful companies. We know that they will make important contributions to our efforts to transform BioLargo into a cleantech juggernaut. With Linda and Christina on board, we couldn’t be more confident in the future for our company.”

Concurrently, board members John S. Runyan and Kent C. (Rick) Roberts II have retired from their positions on the Board of Directors where they served faithfully for over a decade. Both will remain as formal Advisors to the Board of Directors as their time permits.

Mr. Calvert commented, “John and Rick have made significant contributions to the company over the years, and we are thankful for their meaningful impact on the company. We look forward to working with them in the future in their roles as Advisors to the board.”

 

About BioLargo, Inc.

BioLargo, Inc. (OTCQB:BLGO) invents, develops, and commercializes innovative technologies in the cleantech space, including for PFAS contamination, advanced water and wastewater treatment, industrial odor and VOC control, air quality control, and infection control. With over 13 years of extensive R&D, BioLargo holds a wide array of issued patents, maintains a robust pipeline of products, and provides full-service environmental engineering. Our approach is to invent or acquire novel technologies and develop them to maturity through our operating subsidiaries. We have developed a number of key channel partnerships to support the reach of our products and services and maximize their commercial potential. With a keen emphasis on collaborations with academic, municipal, and commercial organizations and associations, BioLargo has proven itself with over 90 awarded grants and numerous pilot projects. We monetize through direct sales, recurring service contracts, licensing agreements, strategic joint venture formation and/or the sale of the IP. See our website at www.BioLargo.com.

Contact Information

Dennis P. Calvert

President and CEO, BioLargo, Inc.

888-400-2863

Safe Harbor Act

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo’s (the “Company”) expectations regarding anticipated revenue and plans for future operations, and may be identified by words such as “we believe”. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of the COVID-19 pandemic on the Company’s business, results of operations, financial condition, and stock price; the effect of global and regional economic conditions on the Company’s business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company’s products. More information on these risks and other potential factors that could affect the Company’s business and financial results is included in the Company’s filings with the SEC, including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.